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most commonly applied for in vivo gene therapy approaches.
The evaluation of vectors during clinical development requires
the production of considerable amounts of highly pure and
potent vectors. Here, we set up a scalable process for AAV
production, using orbitally shaken bioreactors and a fully
characterized suspension-adapted cell line, HEKExpress. We
conducted a proof-of-concept production of AAV2/8 and
AAV2/9 vectors using HEKExpress cells. Furthermore, we
compared the production of AAV2/9 vectors using this suspen-
sion cell line to classical protocols based on adherent HEK293
cells to demonstrate bioequivalence in vitro and in vivo.
Following upstream processing, we puriﬁed vectors via
gradient centrifugation and immunoafﬁnity chromatography.
The in vitro characterization revealed differences due to the
puriﬁcation method, as well as the transfection protocol and
the corresponding HEK293 cell line. The puriﬁcation method
and cell line used also affected in vivo transduction efﬁciency
after bilateral injection of AAV2/9 vectors expressing a GFP
reporter fused with a nuclear localization signal (AAV2/9-
CBA-nlsGFP) into the striatum of adult mice. These results
show that AAV vectors deriving from suspension HEKExpress
cells are bioequivalent and may exhibit higher potency than
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Viral vectors have a long track record in therapeutic gene delivery and
intervention. Current efforts are starting to bear fruit, as more viral
vector therapies are reaching the later stages of clinical development.
Glybera, an adeno-associated virus serotype 1 (AAV1)-based gene
therapy approach to treat lipoprotein lipase deﬁciency, was the ﬁrst
viral vector therapeutic approved by the European Medicines Agency
(EMA) (in 2012).1,2 Recently, the US Food and Drug Administration
(FDA) has approved Spark Therapeutic’s Luxturna, another AAV-
based gene therapy, to treat an inherited condition that leads to blind-
ness. All viral vector therapeutics that received “Priority Medicine”
status by the EMA in 2017 are recombinant adeno-associated virus
(rAAV) vectors, reﬂecting the popularity of AAV vector technology
and its therapeutic potential.314 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20
This is an open access article under the CC BY license (http://creativDiscovered in 1965, AAVs are non-pathogenic members of the
Dependovirus genus of parvoviruses, endemic in humans.4,5 Produc-
tive infection requires co-infection with a helper virus, such as adeno-
virus or herpes virus. Since the discovery of AAV, a variety of
serotypes and variants have been described and characterized, with
AAV2 being the most extensively studied. The single-stranded
DNA (ssDNA) genome, which is ﬂanked by two inverted terminal
repeats (ITRs), can be replaced by any gene (maximum z5kb) to
create a rAAV vector genome.6 AAV vector technology has advan-
tages that make it one of the most attractive solutions for therapeutic
gene delivery. It is possible to transduce both dividing and non-
dividing cells with AAV vectors, and long-term transgene expression
can be achieved in post-mitotic cells. Furthermore, AAV exhibits low
immunogenicity, and no adverse events have been reported during
past clinical trials.7
Hurdles and limitations have become apparent as the technology has
matured and product development has intensiﬁed, prohibiting the
full translation of basic research to the clinic and the market. Testing
a therapeutic candidate in clinical trials poses a serious challenge con-
cerning scale-up. A process that allows the robust and reproducible
manufacturing of a drug at the required scale, with the required yields
and purity, is key for its clinical development and commercial
viability.
Despite the availability of scalable methods and protocols for produc-
tion, transient transfection of adherent HEK293 cells remains the
most commonly used method to produce AAV vectors for pre-clin-
ical research. The transfection of Sf9 cells, using the baculovirus19 ª 2018 The Author(s).
ecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgexpression vector system (BEVS), allows large-scale production with
high-volumetric yields.8,9 However, this expression system is less
frequently used in basic research. Recently, several groups have
demonstrated the technical feasibility of scaling up AAV production
by transfecting suspension-adapted HEK293 cells.10,11
Here, we report the implementation of a scalable process for the
production of AAV vectors using suspension HEKExpress cells in
orbitally shaken bioreactors (OSRs) and polyethylenimine (PEI)-
mediated transient transfection. Key features of OSR technology are
high gas transfer rates, low mixing times, and low speciﬁc power con-
sumption.12–14 OSRs can be operated on a scale from 5 mL to 1,000 L
and have shown excellent scalability.15 We produced AAV2/8 and
AAV2/9 vectors in suspension using orbital shaken bioreactors.
Additionally, we conducted a side-by-side comparison of AAV2/9
production in adherent and suspension-adapted HEK293 cells to vali-
date and demonstrate bioequivalence. The adherent cells were trans-
fected following an established protocol for calcium phosphate
transfection.
The purpose of this study was to validate a newly implemented
process that offers scalability, compliance, and economic advantages.
We demonstrated the potency of vectors produced using suspension-
adapted HEK293 cells by comparing them with vectors produced in
classical adherent HEK293 cell cultures. We assessed bioequivalence
by analyzing the vectors produced by the two methods, both in vitro
(immunoblot, electron microscopy [EM], ELISA) and in vivo, to
determine transduction efﬁciency in the CNS.
RESULTS
Cultivation and Transfection of HEK293 Cells in Suspension
We selected the HEKExpress cell line, which has been previously
adapted to growth in suspension and characterized according to
good manufacturing practice (GMP) guidelines by the provider. We
assessed the capacity of HEKExpress cells to be maintained in
serum-free F17 Freestyle medium using OSRs for scalable production.
The advantage of the OSR system for small and larger scale cell culture
under suspension conditions has been veriﬁed in direct compari-
sons.12,13,15–17 OSR technology has been validated by its widespread
use in industry and is used at small scale (10–30 mL scale) by most
of the pharmaceutical companies involved in protein expression,
particularly for process development and prediction of the theoretical
yieldwhen scaling processes up, even if scale-up is performed in stirred
tank bioreactors. We implemented the OSR platform for AAV pro-
duction by initially recording the growth proﬁles of the HEKExpress
cells in Freestyle F17 medium, principally cell density and viability
(Figure S1). Small-scale transfections were carried out using a protocol
previously described by Chahal et al.10We used 25-kDa linear PEI as a
transfection reagent. PEI with these speciﬁcations can be obtained in
GMP quality. For vector production, we applied a two-plasmid
system, including a helper plasmid (pDP8 or pDP9) and a shuttle
plasmid (AM/CBA-EGFP-WPRE-bGH or AAV-cytomegalovirus
(CMV)-GFP). For transfections, PEI and plasmid DNA were mixed
and incubated in F17 medium before being added to a diluted cellMolecuculture (1  106 cells/mL). The possibility to dilute the cell culture
and perform the transfection in the presence of conditioned medium,
without requiringmedium exchange, is a key feature for a scalable vec-
tormanufacturing process.We observed high viability throughout the
exponential growth of the cells, as well as high transfection efﬁciencies
and rAAV synthesis (Figure S1). The amount of produced intracel-
lular vector peaked at 72 hr, in accordance with previous studies.18
Production and Purification of rAAV Vectors for a Comparative
Study
The main objective of this study was to investigate the production of
AAV vectors in suspension using OSR. Furthermore, we aimed at
comparing the yield and potency of vectors produced using PEI-medi-
ated transfection of HEKExpress cell suspensions with that using cal-
cium phosphate-mediated transfection of adherent AAV293 cells
(Figure 1). We produced AAV2/8, expressing a GFP reporter
(AAV2/8-CMV-GFP). Following this ﬁrst feasibility study, we used
the same protocol to produce AAV2/9, expressing a GFP reporter
fused with a nuclear localization signal (AAV2/9-CBA-nlsGFP). The
AAV8 and AAV9 serotypes were chosen because they are potent vec-
tors for CNS gene delivery.19–21Weproduced these vectors at a scale of
500mL (n = 2) using orbital shaken cell suspensions and harvested the
cells 72 hr post-transfection. The AAV2/9 vector was in parallel pro-
duced with adherent cells using a classical protocol for side-by-side
comparison. The transfection efﬁciencies of adherent cells using
calcium phosphate (83%–86%) were higher as compared with suspen-
sion cells and PEI-mediated transfection (60%–61%) (Table 1). How-
ever, the number of cells in suspension (1  109 cells per batch) was
2-fold higher than the number of adherent cells 72 hr post-transfec-
tion. Thus, the total number of cells expressing the nuclear GFP trans-
gene was higher for the transfected cells in suspension.
In addition to the comparison of production methods, we also
compared the puriﬁcation of vectors via iodixanol gradient centrifu-
gation (IGC) and immunoafﬁnity chromatography (IAC) (Figure 1).
Gradient centrifugation puriﬁcation is commonly used for lab-scale
and cell-pellet harvesting.22 This approach is not suitable for studies
in large-animal models or clinical trials, because it would be very
laborious to process larger liquid volumes.We thus tested puriﬁcation
by chromatographic capture via afﬁnity ligands, which is scalable
and compliant. We chose the POROS CaptureSelect AAV8 and
AAV9 resins for IAC as single-step puriﬁcation. Chromatographic
capture with this resin signiﬁcantly reduced impurities in a single
process step. The nature of the resin and its mechanical resistance
to pressures up to 10 MPa allows the application of high linear veloc-
ities. Hence it is ideally suitable for processing large liquid volumes in
a manufacturing scale.
Titration of AAV2/8 and AAV2/9 Vectors
The AAV2/8 (HEKExpress) and AAV2/9 (HEKExpress and
AAV293) were titrated using a universal real-time PCR method for
the detection of AAV sequences based on primers recognizing the
ITR.23 The AAV8 reference material was used as an internal control.
Viral genome (VG) quantiﬁcation by qPCR showed that the VGlar Therapy: Methods & Clinical Development Vol. 13 June 2019 15
Figure 1. Scheme for the Side-by-Side Comparison of Production Methods and Purification Procedures
HEK293 cells were transfected using calcium phosphate transfection for adherent AAV293 cells grown in cell factories and PEI for HEKExpress suspension cells grown in
Tubespin 600 bioreactors. A total of 5  108 cells (500 mL) per batch were transfected and harvested 72 hr post-transfection. Lysates were purified via gradient
ultracentrifugation (IGC) or immunoaffinity chromatography (IAC). Four vector preparations (AAV293 IGC, HEKExpress IGC, AAV293 IAC, and HEKExpress IAC) were
generated for this study.
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very similar, with 1.14 1011 and 1.07 1011 VGs (Figure 2A). A re-
covery of 35.6% of the initial load was obtained with the IGC (total of
4.05 1010 VGs), whereas 17.9% of vectors (total of 1.91 1010 VGs)
was recovered with IAC.
Quantiﬁcation of AAV2/9 vector preparation from adherent and
suspension cells showed the yields of the vector preparations to be
between 2.5  1010 and 1.5  1011 VGs after puriﬁcation. The VG
concentration in batches that were puriﬁed via IGC was higher
than their corresponding batches puriﬁed via IAC; this is in agree-
ment with the ﬁnding of the AAV2/8 puriﬁcation (Figure 2B).
Because the initial input was similar before puriﬁcation, it is likely
that this difference is due to higher loss of VG-containing particles
when the vector was puriﬁed by IAC.
In Vitro Analysis of AAV2/9 Vectors from Suspension and
Adherent Cell Lines
We conducted various in vitro assays to characterize the AAV2/9 vec-
tor preparations in order to investigate possible differences between
suspension and adherent cell lines. Initially we characterized the
AAV2/9 batches by performing SDS-PAGE followed by Coomassie16 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20blue staining. The applied volumes were normalized based on VG
content. Staining showed the abundant presence of VP1, VP2, and
VP3 proteins in the vector preparation and conﬁrmed the efﬁcient
removal of protein impurities from the vector batches isolated by
IGC and IAC (Figure 3A). We further analyzed the presence of VP
proteins by performing western blot analysis with the monoclonal
VP antibody B1 (Figure 3B). The ratios between the amounts of
VP1, VP2, and VP3 were similar for all four AAV2/9 batches by
band-intensity measurements (Figure 3A). The VP band intensities
were higher in the HEKExpress IAC batch (Figure 3B), consistent
with the ELISA data (Figure 3C), given that protein loading was
normalized to the VG content of the samples. This suggests that
AAV2/9 produced in HEKExpress cells and puriﬁed by IAC contains
a higher proportion of empty particles. We also detected protein
bands from 30 to 50 kDa in the IAC-puriﬁed preparations by western
blotting. Their intensity correlated with the overall amount of VP
protein. These protein impurities should have been removed during
ultraﬁltration with a molecular weight (MW) of 100 kDa, given their
size. Thus, the impurities are likely product related, because the most
intense signals were found in the preparation that had the overall
highest VP protein concentration and were detected with the anti-
VP antibody B1 (Figure 3B, HEKExpress IAC).19
Table 1. Summary of Parameters for Batch Production Using Adherent and Suspension-Adapted HEK293 Cells
Cell Line
AAV293 (Adherent) HEKExpress (Suspension)
AAV293 1 (IGC) AAV293 2 (IAC) HEKExpress (IGC) HEKExpress (IAC)
Bioreactors per batch 5 cell factories (500 cm2) 5 cell factories (500 cm2) 2 TubeSpin 600 2 TubeSpin 600
Medium 500 mL DMEM (+FBS) 500 mL DMEM (+FBS) 500 mL F17 500 mL F17
Cell number at transfection z500  106a z500  106a 500  106 500  106
Cell number at harvest 456  106 480  106 1  109 1.1  109
Plasmid DNA per batch 1.5 mg 1.5 mg 0.75 mg 0.75 mg
Transfection method calcium phosphate calcium phosphate PEI PEI
Transfection efﬁciency 83%b 86%b 60% 61%
AAV293 cells were seeded with 20  106 cells per cell factory (100 cm2). HEKExpress cells were seeded at 1  106 cells/mL. All cultures were incubated at 37C for 72 hr. Cells in
suspension were incubated with a shaking frequency of 180 rpm. Transfection efﬁciencies for adherent cell batches were determined by manual counting of GFP-positive cells, whereas
that of cells in suspension was measured by ﬂow cytometry.
aApproximate cell number calculated based on the conﬂuence of adherent cultures.
bDetermined by manual counting using a ﬂuorescence microscope and hemocytometer.
www.moleculartherapy.orgWe next determined the total amount of intact AAV2/9 virions
by ELISA, according to the manufacturer’s protocol. The ELISA assay
showed that similar quantities of assembled capsids (1.4–1.9  1013)
could be obtained from either adherent or suspension cultures, using
IGC as the puriﬁcation method (Figure 3C). However, when the
vector was puriﬁed by IAC, the number of particles produced by
HEKExpress cells reached 3.4 1013. It is at this stage that the origin
of the difference between total capsids and total VGs for HEKExpress
cells, in particular for the IAC protocol, is unclear. We hypothesize
that the high capsid concentration may have led to competition for
afﬁnity ligands on the resin, and thus ultimately to a lower VG recov-
ery. Furthermore, we cannot exclude that, given the high capsid con-
centration, vector aggregation occurred after concentration.
The production of full genome-containing particles determines the
efﬁcacy of a vector preparation. However, the presence of empty
particles is also an important parameter in vector quality control.
We analyzed vector preparations via negative stain transmission
EM (TEM) to further determine the ratio of genome-containing
to empty particles (Figure 4). Empty and full particles are clearly
distinguishable by uranyl formate staining, which was used to obtain
higher resolution than that obtained with uranyl acetate. We
counted the particles and calculated the full-to-empty ratio. As ex-
pected, vectors puriﬁed with IGC exhibited a higher full-to-empty
particle ratio (AAV293 IGC: 5.2 and HEKExpress IGC: 1.4) than
preparations obtained via IAC (AAV293 IAC: 0.3 and HEKExpress
IAC: 0.1). IAC does not allow the separation of full and empty vec-
tor particles, because it is based on afﬁnity toward conformational
epitopes on the surface of the capsid. In contrast, IGC is based on
particle density, which allows the separation of full and empty
vectors.
In Vivo Analysis of Transduction Efficiency and Tropism
CNS gene delivery was tested by intracerebrally injecting four mice
with each of the AAV2/9-CBA- nuclear localized GFP (nlsGFP) vec-
tor preparations. We bilaterally injected a total of 3  107 VGs in aMolecuvolume of 2 mL into the striatum. The vector dose was chosen to opti-
mize the quantiﬁcation and comparability of vector preparations, but
not to maximize either the global level of transduction or vector diffu-
sion. The mice were sacriﬁced 4 weeks after injection to assess AAV2/
9-mediated transduction based on the number of GFP-positive cells.
Global transduction was assessed and GFP epiﬂuorescence measured
for all sections via a microscope slide scanner. There was strong
nuclear GFP expression over large portions of the striatum for all
preparations (Figure 5). Preparations puriﬁed via IGC showed a sta-
tistically signiﬁcantly higher median transduction efﬁciency than
those prepared by IAC (Figure 6A). Furthermore, preparations
derived fromHEKExpress cells showed a higher median transduction
efﬁciency (67.1%), regardless of the puriﬁcation method (Figure 6C).
Overall, the production of cell suspension-generated AAV2/9 vectors
was at least as efﬁcient as that by adherent cell cultures with respect to
transduction efﬁciency. We next investigated the colocalization of
nlsGFP and the neuronal marker neuronbal nuclei (NeuN) to assess
the tropism of the vectors. All four vector preparations displayed a
similar tropism for neurons, with more than 80% of all transduced
cells being NeuN-positive (Figure 6B). Furthermore, the proportion
of GFP-positive neurons was consistent with the overall transduction
efﬁciency. Two-way ANOVA revealed a statistically signiﬁcant differ-
ence between groups depending on the puriﬁcation method.
In conclusion, the results demonstrate that vectors deriving from sus-
pension or adherent cell cultures exhibit similar potency and tropism
when injected into the CNS of mice. Overall, these results show that
transient transfection of suspension cell cultures is a scalable method
for the production of AAV2/9 vectors, which can be used for effective
gene delivery to the CNS.
DISCUSSION
Large amounts of vector are required for the validation of AAV
vectors in pre-clinical animal studies and later for clinical trials. It
is thus necessary to manufacture such vectors at a sufﬁcient scalelar Therapy: Methods & Clinical Development Vol. 13 June 2019 17
Figure 2. Quantification of AAV2/9 Vectors
(A) Quantification of AAV2/8 viral genomes in lysates and purified vector prepara-
tions. The total yield was calculated based on the determined concentration and the
fraction volume of the preparation. (B) Quantification of AAV2/9 viral genomes in IGC
and IAC purified preparations deriving from HEKExpress (suspension) and AAV293
(adherent) cell lines.
Molecular Therapy: Methods & Clinical Developmentusing cGMP-compliant processes to obtain the required quantity and
quality. One commonly used AAV production platform for pre-clin-
ical research is based on the plasmid-based transfection of adherent
HEK293 cells grown in serum-containing media. This production
method is difﬁcult to scale up, labor intensive, and incompatible
with current GMP-compliant manufacturing practices. In this
comparative study, we demonstrated the production of an AAV2/9
vector using a scalable protocol for the transfection of HEKExpress
cells in suspension and their puriﬁcation, including a scalable IAC
procedure. We characterized the vector preparations via in vitro anal-
ysis, providing evidence for the bioequivalence of vectors derived
from adherent cells and cells in suspension, and ﬁnally veriﬁed their
transduction potency in the CNS of mice.
The proof of concept for the serum-free production of AAV vectors,
using HEK293 cells in suspension, in the absence of helper viruses,
has been described as early as 2007.18,24 The use of serum-free me-
dium was a ﬁrst step toward cGMP compliance, because it decreases
the risk for contamination with adventitious agents.25 Furthermore,
virus production using cells in suspension is scalable, as opposed to
production with adherent cells.26
The use of OSRs allows the adaption and cultivation of HEK293
cells in suspension at high viabilities. OSRs are available as sin-
gle-use bioreactor systems up to a scale of 1,000 L.15 The mixing
principle of such reactors is based on horizontal movement and
shaking of the entire reactor, in contrast with the mixing of stirred
tank bioreactors with an impeller. Key features of OSR technology
are high gas transfer rates, low mixing times, and low speciﬁc power
consumption.12,13,27 These characteristics make OSR technology
one of the most promising disposable bioreactor platforms for
mammalian and insect cell culture for both small- and large-scale
operation.14,15,28,2918 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20Previous studies have demonstrated that parameters, such as the
amount of DNA, DNA-to-PEI ratio, and cell density at the time of
transfection, as well as the use of butyrate or butyric acid, the medium,
and the process mode in general (fed-batch, perfusion), are critical to
maximize yields and decrease costs.10,11,24,30–32 For our study, the
total amount of DNA per cell and the DNA-to-PEI ratio for transient
transfection of HEKExpress cells were based on previously optimized
protocols.33,34 Of note, this protocol reduced the amount of plasmid
DNA used for PEI transfection of cells in suspension by 50% relative
to that used for calcium phosphate transfection (Table 1). This is one
obvious advantage of the PEI-based transfection of HEK293 cells in
suspension, because highly pure plasma DNA remains one of the
main cost drivers of transient production processes.
In parallel to process development, which aims to optimize upstream
processing, downstream processing, particularly methods for the scal-
able puriﬁcation of AAV vectors, has been another area of intense in-
terest. Various methods have been explored for the puriﬁcation of
AAV vectors.35–42 The most commonly used is iodixanol or CsCl
gradient ultracentrifugation. However, methods based on discontin-
uous centrifugation are not feasible for large-scale manufacturing.
The processing of large volumes of cell culture lysate would be
extremely difﬁcult to implement in a GMP-compliant manner.
Nevertheless, these methods are frequently used and are suitable for
most basic research applications and pre-clinical in vivo studies.43
Furthermore, gradient ultracentrifugation results in the very efﬁcient
separation of empty from full AAV vector particles. In contrast, afﬁn-
ity chromatography, although it is readily scalable and highly selec-
tive, does not discriminate between full and empty particles.44 By
comparing IGC and IAC, we demonstrated that the removal of empty
particles improved the overall transduction efﬁciency upon injection
of vectors into the striatum. High vector concentrations are desirable
for applications in the CNS, because the volume that can be delivered
is limited. Thus, the removal of empty particles is a prerequisite to
increase the concentration of infectious vectors and avoid the aggre-
gation of vector particles. For applications outside of the CNS, partic-
ularly systemic delivery, the elimination of empty particles is even
more important to decrease potential immunogenicity and avoid
possible adverse events following the immediate immune response.
Ion-exchange chromatography is the only chromatographic method
that has been described for the separation of full and empty particles,
based on different net charges of the respective capsids.39,45,46 In
GMP processes, a minimum of two puriﬁcation procedures are
usually combined to achieve the required speciﬁcations in terms of
product purity. Combining iodixanol density ultracentrifugation
and chromatography has been successfully used for the production
of clinical-grade AAV, but this strategy is difﬁcult to scale up.47 As
an alternative, vectors puriﬁed via afﬁnity chromatography using
the Poros CaptureSelect AAV9 resin, followed by anion exchange
chromatography, have been demonstrated to yield high purity and
partially remove empty particles.45,48,49
We tested the potency of the different AAV2/9 vectors by assessing
cell transduction following intra-striatal injection in adult mice.19
Figure 3. Characterization and In Vitro Analysis of Vector Preparations
(A) The molecular weight of VP1 (87 kDa), VP2 (72 kDa), and VP3 (62 kDa) proteins is indicated. A total of 3 109 VGs were loaded per well, and the nitrocellulose membrane
was stained with Coomassie blue. (B) Western blot analysis with an anti-VP antibody B1 (5  107 VGs per well). (C) The production of assembled capsids was analyzed by
capsid ELISA analysis specific to AAV2/9. The total amount of capsid was calculated based on the determined concentration and the corresponding fraction volume.
www.moleculartherapy.orgThe dose of AAV2/9 was not chosen to maximize diffusion and global
transduction, but to facilitate the side-by-side comparison of the
different AAV batches. AAV2/9, under the control of the chicken
b-actin (CBA) promoter, induced high expression of the transgene,
and GFP-positive cells were widely distributed throughout the in-
jected hemisphere,21,50–54 as already reported. Co-localization with
the neuronal marker NeuN conﬁrmed that the GFP-positive cells
were predominantly neurons. Furthermore, the NeuN/DAPI ratio
showed that neurons represented 60%–65% of striatal cells, in agree-
ment with other studies.55 Our in vivo data show that the puriﬁcation
method, and thus the ratio of full to empty particles, had a limited but
statistically signiﬁcant effect on transduction efﬁciency. This ﬁnding
demonstrates the feasibility of producing AAV vectors using the
developed process, according to the requirements for efﬁcient gene
delivery to the CNS.
MATERIALS AND METHODS
Plasmids
The AM/CBA-EGFP-WPRE-bGH plasmid was kindly provided by
Prof. During (Auckland, New Zealand).56 The CBA promoter was
ﬁrst described by Niwa et al.57 The 1.7-kb chicken b-actin promoter
and CMV enhancer is fused to exon 1 (90 bp) of the chicken b-actin
gene, a hybrid chicken b-actin and rabbit b-globin intron (917 bp),
and rabbit b-globin exon 3 (55 bp), and is also called CB or CAG in
the literature. The EGFP reporter gene was removed by BamHI/
EcoRV digestion and replaced by a gateway cassette (reading frame
A cassette; Invitrogen) from the pBS-Gateway plasmid digested with
BglII/EcoRV. Finally, a Gateway LR Clonase reaction (Invitrogen,
Thermo Fisher Scientiﬁc) was performed with the resulting plasmid
(pAAV2ss-CBA-Gateway-WPRE-bGH) and pENTR-AcGFP1nuc
(derived from Clontech pAcGFP1-Nuc) to produce pAAV2-CBA-
nlsGFP-WPRE-bGH. The pAAV-CMV-EGFP plasmid was ob-Molecutained by inserting the EGFP cDNA from the pAAV-CMV-MCS
plasmid (Agilent, Santa Clara, CA, USA) using standard cloning
procedures. The pDP8 (Plasmid Factory, Bielefeld, Germany) or
pDP9rs-gck plasmid (kindly provided by Dr. Jurgen Kleinschmidt,
Heidelberg, Germany) was used for producing the AAV8 and
AAV9 serotypes, respectively.
Cell Culture
The HEKExpress cell line is the progeny of an adherently growing cell
population originally called HEK293 ATCC CRL-1573, obtained
from the American Type Culture Collection in 1996. This cell line
was weaned off fetal bovine serum (FBS) and adapted to suspension
culture over a long period (months) at the laboratory of Cellular
Biotechnology, EPFL. The cells were grown in suspension culture in
several different animal-component-free media, initially in Spinner
Flasks (30–50 rpm) and later in OrbShake tubes (50 mL), under
shaking conditions between 150 and 200 rpm (displacement radius,
50 mm). During this long-term culture, over many months, sub-
cultivations were executed at shorter time intervals than typically
performed. This resulted in cultures that had a very high degree of
single-cell characteristics, reducing the trend of other suspension-
adapted 293 cells to aggregate. In 2004, a culture of these HEK293
cells was transferred to ExcellGene (Monthey, Switzerland) and
extensively cultured, eventually in EX CELL 293 medium (Sigma-
Aldrich, Buchs, Switzerland), to obtain a very fast-growing and liter-
ally aggregate-free cell culture, from which a cell bank (500 vials
at >20 106 cells/vial, 2008-11-12), maintained at80C, was gener-
ated in 2008. This bank, now called “HEKExpress XLG1.0 MCB,” has
been extensively tested using most available safety and characteriza-
tion tests. It is free of human, mouse, and bovine viruses, and infec-
tion with any known adventitious agent, such as mycoplasma, bacte-
ria, or fungi. This non-cloned cell population has a good growth rate,lar Therapy: Methods & Clinical Development Vol. 13 June 2019 19
Figure 4. Analysis of AAV2/9 Vectors via Negative-
Stain Transmission Electron Microscopy
Representative images were captured at different positions
on the grid. (A) AAV293 IGC particles with a full-to-empty
ratio of 5.2, (B) HEKExpress IGC particles with a full-to-
empty ratio of 1.4, (C) AAV293 IAC particles with a full-to-
empty ratio of 0.3, and (D) HEKExpress IAC particles with a
full-to-empty ratio of 0.1. One exemplary empty particle is
highlighted by the red circle. Empty particles can be
distinguished based on the accumulation of stain in the
particle center. The black arrow indicates impurities found
exclusively in preparations derived from gradient ultracen-
trifugation (identified by previous studies as ferritin11).
The white arrow highlights impurities that we found only in
the AAV293 IGC preparation, which also appeared to
contain the highest amount of impurities for the SDS-PAGE
analysis.
Molecular Therapy: Methods & Clinical Developmentwith a maximal cell density in batches of approximately 4–5  106
cells/mL in EX CELL 293 medium, and a doubling time of approxi-
mately 24 hr. It has proven to be highly transfectable, with excellent
expression levels for recombinant protein production. The cells can
be easily transferred to and cultivated in several commercially avail-
able media that support suspension cultures.
HEK293 cells in suspension were routinely cultivated in a 50-tube
TubeSpin bioreactor (TS50; TPP, Trasadingen, Switzerland) in vol-
umes of 5–10 mL serum-free Freestyle F17 medium supplemented
with 4 mM GlutaMAX (Thermo Fisher Scientiﬁc, Zug, Switzerland).
Cells were orbitally shaken at 180 rpm at 37C with 5% CO2 and 85%
humidity in ISF-4-W incubators (Kühner, Birsfelden, Switzerland).
Cells were seeded at 0.5  106 cells/mL, independent of the cell
line, and passaged twice per week by dilution into fresh medium.
Adherent HEK293 cells, called AAV293 (Agilent Technologies, Basel,
Switzerland), were grown in T-ﬂasks (25 or 75 cm2) in DMEM con-
taining 10% FBS. Cells were seeded at 15%–20% conﬂuence and were
passaged twice per week before reaching 100% conﬂuence.
Transient Transfection of Cells in Suspension
Three to four days before the planned transfection, cells were diluted
with fresh medium to a cell density of 0.5–1  106 cells/mL in an
appropriate volume for the intended scale of production (approxi-20 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019mately a tenth of the production volume). On
the day of transfection, cells were counted and
diluted to a density of 1  106 cells/mL. The
transfection cocktail was prepared by adding
pDNA and then PEI into F17 medium, to a total
volume corresponding to 5% of the production
volume. The amount of pDNA and the
PEI:pDNA ratio must be optimized and depend
on the vector, the transgene, and the cell line
used for production. The cocktail was then mixed
and incubated at room temperature for 10 min.Complex formation was veriﬁed by the increase in the turbidity
of the transfection cocktail. Following incubation, the transfection
cocktail was added to the cell culture, followed by the addition of
CDM4HEK293 medium, corresponding to 10% of the initial cell
culture volume after dilution (GE Healthcare, HyClone).
For each of the TubeSpin 600 bioreactors, a separate transfection mix
was prepared in a 50-mL centrifuge tube. First, 375 mg of plasmid
DNA was added to 12.5 mL of F17 medium. Equimolar amounts of
the shuttle and helper plasmids were used. Subsequently, 750 mg of
PEI was added to the mix, resulting in a DNA:PEI ratio of 1:2. The
tubes were quickly vortexed and then incubated at room temperature
for 10 min before adding the mixture to the cell cultures.
Transient Transfection of Adherent Cells
The production with adherent cells was carried with 10 cell factories
(500 cm2), with 5 cell factories considered as one batch. On the day
before transfection, cells were seeded to a density of 4  107 cells/
cell factory in 100 mL of DMEM. A transfection mix of 10 mL was
prepared for each cell factory. First, 200 mg of helper and 100 mg of
shuttle plasmid were added to 2.5 mL of a 0.5 M calcium chloride so-
lution. The mix was than adjusted to 5 mL with DNase-free water
before the addition of 5 mL of a 2 HEPES buffered saline (HBS)
buffer. The transfection mix was then incubated at room temperature
for 10 min before adding it drop-wise to the cell factories. Six hours
Figure 5. GFP Epifluorescence 4Weeks after Injection
of Respective AAV2/9 Vectors into the Striatum of
7-Week-Old C57BL/6 Mice
Each vector was injected at a dose of 3  107 VGs. De-
picted sections are in proximity to the injection site. The
white scale bar represents 1,000 mm.
www.moleculartherapy.orgpost-transfection the medium of the cell factories was changed and
the DMEM replaced by EpiSerf (Thermo Fisher Scientiﬁc, Zug,
Switzerland).
Harvesting, Cell Lysis, and Clarification
After 72 hr (depending on the vector or transgene), the transfection
was stopped, the cells counted, the viability determined, and the trans-
fection efﬁciency assessed using a BD Accuri C6 (BD Biosciences,
Allschwil, Switzerland) ﬂow cytometer. The cells are then collected
via centrifugation. The pellets were carefully resuspended and washed
with phosphate buffer (pH 7.4). After another round of centrifugation,
the supernatant was discarded and the pellet frozen at 80C.
For further processing the cell pellet was thawed at 37C and resus-
pended in phosphate buffer (pH 7.4) containing 2 mMMgCl2. A vol-
ume of buffer 10 times that of the packed cells was added. Cells were
lysed via three freeze-thaw cycles. 3-[(3-Cholamidopropyl)dimethy-
lammonio]-1-propanesulfonate (CHAPS) (0.5%) was then added to
the lysate and the tubes mixed well and incubated at 37C for
30 min. Following lysis, 5 U Benzonase or DNase I/million cells
(cell number at the time of harvest) was added to the lysate and the
tubes incubated at 37C for 1 hr to digest the genomic DNA (observ-
able reduction of the viscosity), residual plasmid DNA, and free VG
replicates. NaCl was then added to a concentration of 150 mM to pre-
vent aggregate formation. The lysate was initially clariﬁed by centri-
fugation at 10,000  g for 15 min.
Purification via IGC
The clariﬁed lysate was transferred to a 30-mL ultracentrifuge tube
(maximal volume = 8 mL) and sequentially underlaid with 15%
(9 mL), 25% (5 mL), 40% (5 mL), and 60% (3 mL) iodixanol solutions
(Axon Lab, Mont-sur-Lausanne, Switzerland; PBS [pH 7.4]) The
centrifugation was carried out using a 70Ti rotor at 350,000  g for
90 min at 4C. After centrifugation, iodixanol fractions were recov-Molecular Therapy: Methodered by piercing the bottom and opening the
top of the centrifuge tube. The ﬁrst 2 mL of the
60% fraction was discarded. The next 5 mL was
collected and transferred into Amicon Ultra-15,
PL100 tubes (Merck, Schaffhausen, Switzerland)
for buffer exchange and concentration.
Purification via IAC
An AKTA Pure chromatography controller (GE
Healthcare, Glattbrugg, Switzerland) and the
POROS CaptureSelect AAV9 resin (Thermo
Fisher Scientiﬁc, Zug, Switzerland) were usedfor IAC. Initially, an Omniﬁt column (Diba Industries, Danbury,
CT, USA) with a diameter of 1 mmwas packed according to the man-
ufacturer’s recommendations (see POROS CaptureSelect AAV
Resins: AAV8, AAV9, AAVXUser Guide). The use of 10 mL of slurry
and a ﬂow rate of 10 mL/min (linear velocityz763 cm/hr) resulted in
a packed column volume of approximately 5.6 mL. The column was
equilibrated with 10 column volume (CV) of equilibration buffer
(10 mM phosphate buffer [pH 7.4]) at a ﬂow rate of 2 mL/min (linear
velocityz152 cm/hr). The clariﬁed lysate was loaded at a ﬂow rate of
1 mL/min (linear velocityz76 cm/hr). The column was then washed
with 5 CV equilibration buffer at a ﬂow rate of 2 mL/min. A pilot
study was performed to optimize the elution conditions (pH step
gradient elution; data not shown). Bound AAV2/9 particles were
recovered by one-step elution using 50 mM citrate buffer (pH 3) at
a ﬂow rate of 2 mL/min. Elution fractions of 5 mL were collected.
Immediately after collection, neutralization buffer (100 mM Tris
[pH 9]) was added to adjust the fractions to pH 7. The 280-nm absor-
bance peak fractions were pooled and further processed. After the
elution step the column was regenerated using 5 M guanidine
hydrochloride.
Buffer Exchange and Concentration via Ultrafiltration
Amicon Ultra-50 or Ultra-15 tubes (Millipore, Zug, Switzerland)
were prepared and washed according to the manufacturer’s instruc-
tions. The collected iodixanol or pH-neutralized elution fractions
were initially transferred to Amicon Ultra-15 tubes (Merck, Schaff-
hausen, Switzerland) and centrifuged at 3,000  g until the volume
was reduced to approximately 500 mL. The concentrate was washed
two times with 12 mL of phosphate buffer (pH 7.4), concentrated,
and subsequently aliquoted for storage at 20C.
AAV Titration (qPCR)
The AAV ITR qPCR was based on a previously published protocol us-
ing the forward ITR primer: 50-GGAACCCCTAGTGATGGAGTT-30,s & Clinical Development Vol. 13 June 2019 21
Figure 6. Boxplot of Transduction Efficiencies of Vector Preparations In Vivo
(A) Quantification based on the detection of GFP-positive cells via confocal microscopy of sections close to the site of injection (two-way ANOVA, Sidak’s multiple comparison
test, p = 0.0014). (B) Analysis of vector tropism based on GFP and NeuN colocalization (two-way ANOVA, Sidak’s multiple comparison test, p = 0.0037). (C) Transduction
efficiency based on GFP expression, pooled according to producer cell lines (two-way ANOVA, Sidak’s multiple comparison test, p = 0.0266).
Molecular Therapy: Methods & Clinical Developmentreverse primer: 50-CGGCCTCAGTGAGCGA-30, and probe: 50-FAM-
CACTCCCTCTCTGCGCGCTCG-TAMRA-30 (Microsynth, Balgach,
Switzerland).23 The 62-bp PCR product was generated using a Rotor
gene (QIAGEN, Basel, Switzerland). The PCR was performed with
the Kapa probe fast qPCR master mix (Sigma-Aldrich, Buchs,
Switzerland) in a 20-mL reaction volume using the following cycle
parameters: 95C for 180 s, then 40 cycles of 95C for 3 s and 60C
for 20 s. AAV8 reference standard material was used as an internal
control.58 This method has a limit of detection of 50 plasmid copies,
which corresponds to 100 ssDNA vector genomes and 200 copies of
ssAAV-ITR.23
Assembled AAV2/9 Capsid ELISA
An ELISA based on a capture antibody detecting a conformational
epitope (ADK9 monoclonal antibody), not present on unassembled
capsid proteins, was used to quantify intact AAV9 recombinant22 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20virions (Bencard, Greifensee, Switzerland). The samples for the stan-
dard curve (lyophilized AAV9) were diluted in assay buffer (1:2 to
1:64, technical duplicates). Aliquots of the AAV2/9 batches were
diluted (1:250,000 to 1:600,000) in assay buffer and incubated 1 hr
at 37C. The wells were washed three times and incubated at 37C
for 1 hr with the anti-AAV9 biotin conjugate according to the man-
ufacturer’s protocol. After three washes, the samples were incubated
with the substrate for 15 min at room temperature. The color reaction
was measured with a photometer at a wavelength of 450 nm. A four-
parameter logistic ﬁt (4PL) curve was used to calculate the particle
titer of the samples.
SDS-PAGE and Western and Dot-Blot Analysis
A total of 3  109 VGs were denatured for 10 min at 98C in
Laemmli-buffer (50 mM Tris-HCl [pH 6.8], 4% SDS, 10% glycerol,
0.1% bromophenol blue, 5% b-mercaptoethanol) and loaded on an19
www.moleculartherapy.orgSDS-PAGE gel (4%–12% Bis-Tris, 50 mM 3-(N-morpholino)pro-
panesulfonic acid [MOPS], 50 mM Tris-base, 0.1% SDS, 1 mM
EDTA [pH 7.7]). The electrophoresis was conducted at 120 V for
60 min. Protein bands were visualized by Coomassie blue staining
(1 hr at room temperature) and de-stained in distilled water
overnight.
For western blot analysis, the proteins were transferred onto a nitro-
cellulose membrane by wet-tank blotting in the corresponding trans-
fer buffer (25 mM Tris-HCl, 192 mM glycine, 20% methanol, 0.03%
SDS) at 50 V for 60min. Themembrane was then blocked with block-
ing buffer (5% milk powder in PBS) for 2 hr at room temperature.
After washing the membrane with PBST buffer (0.1% Tween), the
blot was probed with primary anti-VP antibody B1 (dilution 1:20
in blocking buffer, mouse monoclonal immunoglobulin G1 [IgG1]
antibody) (PROGEN, Heidelberg, Germany) and secondary horse-
radish-peroxidase-labeled polyclonal rabbit anti-mouse antibodies
(diluted 1:1,000 in blocking buffer) (Agilent Technologies, Basel,
Switzerland).
Assembled AAV2/9 capsids were evaluated by applying 1  106 and
5  106 VGs to a nitrocellulose membrane (soaked in transfer buffer
for 5 min), placed in a microﬁltration apparatus, under non-dena-
turing conditions. A vacuum was applied and samples pipetted
onto the membrane. The wells were then washed with PBST (0.1%
Tween) before the membrane was blocked with blocking buffer. For
detection of assembled particles, the membrane was incubated with
the AAV9-speciﬁc antibody, ADK9 (diluted 1:2 in blocking buffer,
mouse monoclonal immunoglobulin A [IgA] kappa) (Progen; Ben-
card, Greifensee, Switzerland).
Negative TEM Staining
A 5-mL drop of sample solution was adsorbed to a glow-discharged
carbon-coated copper grid (Canemco & Marivac, Canada), washed
with deionized water, and stained with 5 mL of 2% uranyl formate.
The samples were imaged at room temperature using a Tecnai Spirit
electron microscope equipped with an LaB6 ﬁlament operated at an
acceleration voltage of 80 kV. Images were taken at magniﬁcations
from 30,000 to 50,000 and recorded with a 4,098  4,098 Eagle
(FEI, the Netherlands) camera. The mean full-to-empty ratio for
the various AAV2/9 batches was calculated based on the quantiﬁca-
tion of four images.
Animals
Eight-week-old female (adult) C57BL/6mice (Janvier, LeGenest-Saint-
Isle, France)were used for the in vivo experiments.Micewere housed in
a speciﬁc pathogen-free (SPF) facility in rat R.BTM.U /R.ICV.6 cages
(Innovive, Paris, France) and simple face Innorack racks (catalog [cat]
no. RS.5.8.40), containing corn cob bedding with ﬁve mice per cage
maximum. The animals were maintained in a controlled-temperature
room (22C ± 1C) under a 14-hr light/10-hr dark cycle. Enrichments
consisted of two wipes, one cardboard tunnel, and one cardboard or
polysulfone house with two entrances and exits. Food (global rodentMolecudiet XP-18, vitamin-fortiﬁed, irradiated at 25 kGy; cat no. 3242; Kliba
Nafag, Kaiseraugst, Switzerland) and water were provided ad libitum.
All experimental procedures were performed in strict accordance
with Swiss regulations concerning the care and use of laboratory ani-
mals (veterinary authorizations: 2782, 2888, and 3073).
Stereotaxic Injections
Mice were anesthetized by the intraperitoneal injection of a mixture
of 100 mg/kg ketamine (Ketasol; Graeub, Bern, Switzerland) and
10 mg/kg xylazine (Rompun; Bayer Health Care, Uznach,
Switzerland). In brief, the head of the mouse was shaved, and the
mouse was placed in the stereotaxic frame (model 963 Ultra Precise
Small Animal Stereotaxic Instrument; Kopf, Tujunga, USA). During
the surgery, the body temperature was controlled with a warming
blanket (CMA 450 Temperature Controller; Phymep, Paris, France)
and the eyes protected with 0.2% Viscotears liquid gel (Novartis,
Switzerland). The scalp was disinfected with liquid povidone-iodine
before incision and skull exposure. A 25G needle ﬁxed to a syringe
holder was used to pierce the skull at the appropriate coordinates.
The stereotaxic coordinates of the striatum used were as follows:
anteroposterior +0.5 mm from bregma, mediolateral ±2 mm and
dorsoventral 3.5 mm from the skull, with the tooth bar set to align
the bregma and lambda. AAV suspensions were injected with a
34-gauge blunt-tip needle (Unimed, Lausanne, Switzerland) linked
to a Hamilton syringe (Hamilton Medical, Bonaduz, Switzerland)
via a polyethylene catheter (Unimed, Lausanne, Switzerland). Mice
received a total volume of 2 mL of AAV on either side of the head,
administered at a rate of 0.2 mL/min. The needles were left in place
for 5 min after the injection and were then slowly removed. The
skin was sutured with 6-0 Prolene suture (B-Braun Medical, Sem-
pach, Switzerland), and healing cream was applied to the scalp
(Bepanthen Plus; Bayer, Leverkusen, Germany). Sterile 0.9% NaCl
(B-Braun Medical, Sempach, Switzerland) was delivered by subcu-
taneous injection to prevent dehydration, and the mice were allowed
to recover on a heating mat. The mice received 2 mg/mL sweetened
acetaminophen (Dafalgan; UPSA, Agen, France) in water for the
3 days following the intervention to reduce pain.
Concentrated viral stocks were thawed on ice and resuspended in PBS
with Pluronic F-68 (Thermo Fisher Scientiﬁc, Zug, Switzerland) by
repeated pipetting before injection. For evaluation of tropism and
transduction efﬁciency of the four AAV preparations in vivo, we in-
jected 3  107 VGs/site (2 mL at 0.2 mL/min) of the AAV2/9-CBA-
nlsGFP preparations into C57BL/6 mice. Animals were sacriﬁced
4 weeks after the injection.
Sample Processing and Immunostaining
The mice were sacriﬁced by an overdose of sodium pentobarbital
(B-Braun Medical, Sempach, Switzerland) and transcardially
perfused at a rate of 20 mL/min with 1 PBS for 1 min and then
4% PFA for 5 min. Brains were removed and post-ﬁxed by incuba-
tion in 4% PFA for 24 hr at 4C. They were then cryoprotected
by incubation in 20% sucrose (Sigma-Aldrich, Buchs, Switzerland)
in 1 PBS for 24 hr and then 30% sucrose in 1 PBS for 24 hr.lar Therapy: Methods & Clinical Development Vol. 13 June 2019 23
Molecular Therapy: Methods & Clinical DevelopmentBrains were then stored at 80C until use. We cut 25-mm-thick
coronal brain sections on a sledge microtome with a freezing stage
at 30C (Leica SM2010R; Biosystems Switzerland, Nunningen,
Switzerland). Slices throughout the striatum were collected and
stored in tubes, as free-ﬂoating slices in anti-freeze solution (25%
glycerol [Sigma-Aldrich, Buchs, Switzerland], 30% ethylene glycol
[Merck, Nottingham, UK], 25% 1 PBS, and 20% Nanopure water).
Slices for direct ﬂuorescence analysis and visualization were
mounted directly on Superfrost+ microscope slides in Vectashield
mounting medium for ﬂuorescence with DAPI (Vector Labs, Bur-
lingame, CA, USA).
For the immunoﬂuorescence labeling of brain sections, free-ﬂoating
slices were washed three times, for 10 min each, in 1 Tris-buff-
ered saline (TBS) and blocked by incubation for 1 hr in 1 TBS
supplemented with 5% normal goat serum (NGS) and 0.1% Triton
X-100. Primary antibodies were diluted in 1 TBS-5% NGS-0.1%
Triton X-100 and incubated overnight with the sections at 4C.
The following primary antibodies were used: rabbit polyclonal
anti-NeuN antibody (1/1,000; Millipore, Zug, Switzerland), mouse
monoclonal anti-S100b antibody (1:2,000; Sigma-Aldrich, Buchs,
Switzerland), and rabbit polyclonal anti-GFAP antibody (1/200;
Dako Schweiz, Basel, Switzerland). The following day, slices were
washed three times for 10 min each with 1 TBS and incubated
for 1 hr at room temperature with goat anti-rabbit IgG Alexa
Fluor 594 (Invitrogen, Life Technologies, Zug, Switzerland) or
goat anti-mouse IgG Alexa Fluor 594 (Invitrogen, Life Technolo-
gies, Zug, Switzerland), diluted 1:1,000 in 1 TBS-0.1% Triton
X-100. Slices were then washed three times, for 10 min each, in
1 TBS and mounted on Superfrost+ slides, in Vectashield Fluo-
rescence mounting medium with DAPI (Vector Labs, Burlingame,
CA, USA).
Images and Quantitative Analysis
Images of each brain slice were acquired with a 20 objective on a
Zeiss Axio Scan Z1 (LSM software, Zeiss; Carl Zeiss Microscopy,
Göttingen, Germany). The images used to quantify GFP-, NeuN-,
and DAPI-positive cells for each batch of AAV were acquired with
a 20 objective on a Zeiss LSM 880 with an Airyscan inverted
confocal microscope (LSM software, Zeiss; Carl Zeiss Microscopy,
Göttingen, Germany). We selected one section for which we acquired
one picture per hemisphere in the center of the transduced area for
each animal, based on the picture acquired on the Zeiss Axio Scan.
Each picture was composed of four tiles with a z stack covering the
whole brain section. The same acquisition parameters were used for
all sections and all experimental groups. One image from the
AAV293 IGC and HEKExpress IAC groups was removed from the
analysis because of limited transduction.
For the quantitative analysis, the background of the images was cor-
rected and then analyzed using an ImageJ spot detection macro,
applying identical thresholds for all images. GFP-positive cells were
measured using the same detection thresholds. Quantiﬁcation was
normalized based on a DAPI-positive cell population.24 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20Statistical Analysis
All data are expressed as the means ± SD. When more than two
groups were compared, a two-way ANOVA with Sidak’s multiple
comparison test was carried out using commercially available soft-
ware (Prism 7.0; GraphPad). The statistical signiﬁcance was set to a
p value <0.05 for all tests.
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